Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511778 · ClinicalTrials.gov registry record · Phase 4
sTErnAl heMostasiS Trial
A Phase 4 study of Excessive Bleeding During Surgery, sponsored by WakeMed Health and Hospitals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06511778: Recruiting Phase 4 study of Excessive Bleeding During Surgery, sponsored by WakeMed Health and Hospitals.
NCT06511778 is a Phase 4 study of Excessive Bleeding During Surgery that is actively recruiting participants, run by WakeMed Health and Hospitals. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06511778, a Phase 4 study of Excessive Bleeding During Surgery, is actively recruiting participants, sponsored by WakeMed Health and Hospitals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Sternal bleeding remains an unsolved problem for cardiac surgery teams costing operative time, blood loss, and distraction from the critical operative field. As such, the following is an investigator-initiated trial to determine whether application of a topical hemostatic agent reduces sternal bleeding during cardiac surgery using sternotomy approach.
Primary Outcome
A sternal bleeding score will be performed independently by surgeon and physician assistant utilizing the SPOT GRADE bleeding scale ranging from 0-5. 0 (no bleeding), 1 (minimal bleeding), 2 (mild bleeding), 3 (moderate bleeding), 4 (severe bleeding), 5 (extreme bleeding) before and after hemostatic agent application
Conditions Studied
Interventions
- DRUG Hemoblast Bellows application
Study Locations (1)
North Carolina
- WakeMed Health and Hospitals - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
What NCT06511778 shows while recruiting
NCT06511778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Excessive Bleeding During Surgery appearing as the primary indexed condition, and to 1 intervention - of which Hemoblast Bellows application is the first listed.
NCT06511778 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06511778 about?
NCT06511778 is a clinical study titled "sTErnAl heMostasiS Trial". Sternal bleeding remains an unsolved problem for cardiac surgery teams costing operative time, blood loss, and distraction from the critical operative field. As such, the following is an investigator-initiated trial to determine whether application of a topical hemostatic agent reduces sternal bleed...
What is the current status of trial NCT06511778?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2024-10-17. Estimated completion is 2026-09.
What conditions does trial NCT06511778 study?
This clinical trial studies the following conditions: Excessive Bleeding During Surgery.
What interventions are being tested in trial NCT06511778?
The interventions under investigation include: Hemoblast Bellows application (DRUG).
Who is sponsoring clinical trial NCT06511778?
This trial is sponsored by WakeMed Health and Hospitals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06511778 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06511778's enrollment target sits among peer trials
60 1125th of 2000 higher than 800 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI